Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.54 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in sertoli cells | 0.75 |
| chemistry Open Targets | compounds already reach it: propafenone hydrochloride, encainide hydrochloride, moricizine +76 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 515 | 0.73 |
| pathways Reactome | 3 pathways; mostly dopamine synapse | 1.00 |
Knock down and overexpress SCN9A in oligodendrocytes; measure evoked dopamine release and dopamine transporter uptake and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- evoked dopamine release and dopamine transporter uptake
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves evoked dopamine release by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of SCN9A in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: evoked dopamine release and dopamine transporter uptake; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Earlier readings: 2026-10-26 0.61; 2026-10-25 0.61; 2026-10-24 0.61; 2026-10-23 0.61.
Sealed predictions
- SCN9A in dopamine neurons, braak-0.02 (p 0.964) → +0.34 (p 0.373)receipt 0166
- SCN9A in oligodendrocytes, braak-0.34 (p 0.371) → +0.19 (p 0.630)receipt 0165
Swarm cases
receipt 0166: SCN9A in dopamine neurons, braak
- power
- full sample +0.39 (p 0.107, n 18), 95% CI -0.09 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.33 (p 0.179, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.32 (p 0.194, n 18). could be the mix.
- skeptic
- leave-one-out range +0.32 to +0.56, sign flips 0; without severely affected donors +0.39 (p 0.107, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN9A in dopamine neurons.
case closed: nothing better to follow up.
receipt 0165: SCN9A in oligodendrocytes, braak
- power
- full sample -0.25 (p 0.315, n 18), 95% CI -0.64 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.19 (p 0.444, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.22 (p 0.379, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.315, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN9A in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts